#Primary Sclerosing Cholangitis (PSC) symptoms

[chiragglobalhospitals]

What is Ulcerative Colitis: A Comprehensive Summary

Ulcerative colitis (UC) is a chronic, inflammatory bowel disease (IBD) characterised by continuous inflammation of the colonic lining, beginning in the rectum and potentially extending proximally throughout the entire colon. UC is limited to the colon and involves only the superficial layers.

UC is a relapsing-remitting condition, meaning it alternates between periods of active disease (flares) and times of little or no symptoms (remission). Its onset can be gradual or sudden, and the severity can range from mild discomfort to life-threatening complications.

When your gut doesn’t feel good, nothing else feels right. Pain, bloating, and unpredictable bowel movements can make you feel helpless. It’s not just physical; it impacts your confidence, routines, and relationships. Many people live with chronic digestive discomfort without knowing that a condition like ulcerative colitis could be the cause, and that it’s treatable.

What are the symptoms of UC? How do I know if I have UC?

The clinical presentation of ulcerative colitis depends on the extent and severity of the disease. Symptoms may develop gradually or suddenly and may vary from person to person.

Intestinal Symptoms

Bloody diarrhoea: This is the hallmark symptom, often with mucus.

Abdominal pain: Commonly crampy and located in the lower left quadrant.

Urgency and pain during defecation: Sudden urge to defecate and a feeling of incomplete evacuation.

Increased frequency of bowel movements: Often more than six times per day during flares.

Passage of stools in sleep causes extreme discomfort and may disrupt sleep.

2. Generalised Symptoms

Fever

Fatigue

Weight loss

Anaemia: Due to chronic blood loss and inflammation.

3. Problems outside of the intestine:

UC is associated with systemic inflammation that can affect other organs:

Arthritis: Especially peripheral joints.

Uveitis and episcleritis: Eye inflammation.

Erythema nodosum and pyoderma gangrenosum: Skin manifestations.

Primary sclerosing cholangitis (PSC): A liver disease that can occur in association with UC.

Why did I get UC? What are the Causes and Risk Factors?

The exact cause of ulcerative colitis remains unknown. It is believed to be the result of a complex interplay of genetic, environmental, immune-related, and microbial factors.

Here are some key contributors:

Genetic Factors

Family history increases the risk significantly. First-degree relatives of individuals with UC are at a higher risk.

2. Immune System Dysfunction

UC is thought to be an autoimmune condition, where the immune system inappropriately attacks the lining of the colon.

3. Environmental Factors

Geography: More common in industrialised countries, particularly in North America and Northern Europe.

Diet: High-fat and high-sugar diets, low intake of fruits and vegetables, and excessive red meat consumption may increase risk.

Smoking: Interestingly, UC is less common in smokers. Some studies suggest that smoking may have a protective effect against UC.

Hygiene hypothesis: Overly sterile environments may lead to immune system dysregulation.

4. Gut bacteria

Alterations in the diversity and composition of intestinal bacteria (dysbiosis) have been noted in UC.

A reduction in beneficial bacteria and an increase in harmful species may contribute to inflammation.

How is Ulcerative Colitis Diagnosed?

The diagnosis of UC is based on a combination of clinical evaluation, laboratory tests, imaging, and endoscopic examination with biopsy.

Laboratory Tests

Complete blood count (CBC): May show anaemia or elevated white blood cell count.

C-reactive protein (CRP) and ESR: Markers of inflammation.

Fecal calprotectin: Elevated in intestinal inflammation.

2. Endoscopy

Colonoscopy with biopsy: The gold standard. Shows continuous inflammation beginning in the rectum. Biopsies confirm mucosal inflammation and rule out infections or dysplasia.

3. Imaging

Abdominal X-rays or CT scans: To assess complications like toxic megacolon or perforation.

Types of Ulcerative Colitis

UC is classified by the extent of colonic involvement:

Ulcerative proctitis: Inflammation limited to the rectum.

Left-sided colitis: Extends from the rectum to the splenic flexure.

Pancolitis: Involves the entire colon.

Do I need treatment for UC? Will I need surgery?

The goal of treatment is to induce and maintain remission, reduce symptoms, and improve quality of life. Therapy depends on disease severity and extent.

The main objective is to suppress inflammation, assist in healing, and sustain remission for as long as possible.

Conclusion

Ulcerative colitis can be a chronic condition, but it doesn’t have to dominate your life. With early diagnosis, an appropriate treatment regimen, and frequent medical check-ups, most individuals can successfully control their symptoms and lead a good quality of life.

Knowing your body, monitoring symptoms, and steering clear of personal triggers can help minimise flare-ups. From medication to diet to surgery, regular contact with your doctor is necessary to get appropriate care at any point.

If you have symptoms of ulcerative colitis or suspect you might, consult a Ulcerative Colitis Specialist at Chirag Hospitals to begin appropriate care.

Continue reading here to know more about: Ulcerative Colitis

[businessindustry]

Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033

The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Primary Sclerosing Cholangitis Market?

The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.

What are Primary Sclerosing Cholangitis?                                                                                                                                             

Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389

What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?

The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Type

Classic PSC

Variant PSC

PSC Associated with Autoimmune Hepatitis

PSC with Cholangiocarcinoma

By Treatment Type

Ursodeoxycholic Acid

Obeticholic Acid

Methotrexate

Corticosteroids

Others

By Route of Administration

Oral

Parental

Others

By End-User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Acorda Therapeutics, Inc.

Gilead Sciences, Inc.

NGM Biopharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Falk Pharma GmbH

Allergan Plc.

Shire Plc.

Durect Corporation

Conatus Pharmaceuticals, Inc.

Sirnaomics, Inc.

Shenzhen HighTide Biopharmaceutical Ltd.

Cymabay Therapeutics

Pliant Therapeutics

Immunic AG

View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[digestive45]

Comprehensive Guide to Liver Diseases: Causes, Symptoms, and Treatment

Comprehensive Guide to Liver Diseases: Causes, Symptoms, and Treatment

16th World Digestive and Liver Diseases Conference from December 17-19,2025 in Dubai, UAE

Introduction

The liver is one of the most vital organs in the human body, responsible for numerous essential functions, including detoxification, protein synthesis, and digestion. However, liver diseases have become a growing global health concern, affecting millions of people every year. Understanding the causes, symptoms, and available treatments for liver diseases is crucial for early detection and effective management.

The 16th World Digestive and Liver Diseases Conference serves as a key platform for medical professionals, researchers, and healthcare providers to discuss the latest advancements and challenges in diagnosing and treating liver diseases. This guide explores the most common liver diseases, their underlying causes, symptoms, and available treatment options.

What is Liver Disease?

Liver disease refers to any condition that negatively impacts the liver's function and health. The liver plays a vital role in processing nutrients, filtering toxins from the blood, and aiding digestion. Damage to the liver can be caused by infections, autoimmune disorders, metabolic issues, genetic predisposition, and lifestyle factors such as alcohol consumption and poor diet.

Types of Liver Diseases

Liver diseases can be categorized into several major types:

1. Hepatitis

Hepatitis is inflammation of the liver, often caused by viral infections (Hepatitis A, B, C, D, and E).

Hepatitis A – Spread through contaminated food and water.

Hepatitis B – Transmitted through blood, semen, and other bodily fluids.

Hepatitis C – Primarily spread through blood contact (e.g., shared needles).

Hepatitis D – Only occurs in individuals with Hepatitis B.

Hepatitis E – Spread through contaminated water.

2. Fatty Liver Disease

Fatty liver disease occurs when excess fat builds up in the liver. It can be:

Non-Alcoholic Fatty Liver Disease (NAFLD): Associated with obesity, diabetes, and poor diet.

Alcoholic Fatty Liver Disease: Caused by excessive alcohol consumption.

3. Cirrhosis

Cirrhosis is the result of long-term damage to the liver, causing scarring (fibrosis). It can lead to liver failure if untreated. Common causes include chronic alcohol abuse, hepatitis, and fatty liver disease.

4. Liver Cancer

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is often linked to hepatitis infection, cirrhosis, and long-term alcohol abuse.

5. Autoimmune Liver Diseases

In autoimmune liver diseases, the body’s immune system mistakenly attacks healthy liver cells. Examples include:

Autoimmune Hepatitis

Primary Biliary Cholangitis (PBC)

Primary Sclerosing Cholangitis (PSC)

6. Genetic Liver Diseases

Inherited liver diseases result from genetic mutations. Examples include:

Hemochromatosis – Excess iron accumulation in the liver.

Wilson’s Disease – Excess copper buildup in the liver.

Causes of Liver Diseases

The underlying causes of liver diseases can vary depending on the type of disease. The most common causes include: ✅ Viral Infections – Hepatitis viruses (A, B, C, D, E). ✅ Alcohol and Substance Abuse – Excessive alcohol consumption damages liver cells. ✅ Poor Diet and Obesity – High-fat, high-sugar diets contribute to fatty liver disease. ✅ Genetic Disorders – Inherited metabolic issues such as hemochromatosis. ✅ Autoimmune Disorders – The immune system attacking liver tissue. ✅ Toxins and Medications – Long-term exposure to certain medications and chemicals.

Symptoms of Liver Diseases

Symptoms of liver disease often appear gradually and may vary based on the type and severity of the condition. Common signs include:

Fatigue and Weakness

Jaundice (Yellowing of the Skin and Eyes)

Abdominal Pain and Swelling

Dark Urine and Pale Stools

Unexplained Weight Loss

Nausea and Vomiting

Itchy Skin

Diagnosis of Liver Diseases

To diagnose liver disease, healthcare providers may use a combination of the following: ✔️ Blood Tests – Liver function tests (LFT) to check enzyme levels and overall liver health. ✔️ Imaging Tests – Ultrasound, CT scan, or MRI to detect abnormalities. ✔️ Liver Biopsy – A sample of liver tissue is examined under a microscope. ✔️ FibroScan – A specialized ultrasound that measures liver stiffness (indicating fibrosis).

Treatment Options for Liver Diseases

The treatment for liver disease depends on the type, severity, and underlying cause.

1. Medications

Antiviral medications for hepatitis B and C.

Immunosuppressive drugs for autoimmune liver diseases.

Chelation therapy for Wilson’s disease and hemochromatosis.

2. Lifestyle Modifications

Maintaining a healthy diet (low in fat and sugar).

Limiting alcohol consumption.

Regular exercise to reduce obesity and improve liver health.

3. Surgical and Interventional Treatments

Liver Transplant: For end-stage liver disease or liver cancer.

Tumor Removal: For localized liver cancer.

TIPS (Transjugular Intrahepatic Portosystemic Shunt): A procedure to treat portal hypertension.

Prevention of Liver Diseases

✅ Vaccination – Vaccines are available for Hepatitis A and B. ✅ Healthy Diet – A balanced diet rich in fruits, vegetables, lean proteins, and whole grains. ✅ Moderate Alcohol Consumption – Limit alcohol intake to reduce liver damage. ✅ Regular Health Checkups – Early detection through routine liver function tests. ✅ Avoid Sharing Needles – Reduces the risk of hepatitis B and C infection.

Latest Advancements in Liver Disease Management

The 16th World Digestive and Liver Diseases Conference highlights recent breakthroughs, including: 🔬 Gene Therapy – Promising research in treating genetic liver diseases. 🦠 New Antiviral Drugs – Improved treatment options for chronic hepatitis. 💉 Non-Invasive Diagnostic Tools – Enhanced imaging techniques for early diagnosis. 🌿 Regenerative Medicine – Research into stem cell therapy for liver regeneration.

Conclusion

Liver diseases are complex but manageable with early detection and proper treatment. The 16th World Digestive and Liver Diseases Conference provides an opportunity for global experts to collaborate and advance research in this critical field. By understanding the causes, symptoms, and treatment options, patients and healthcare providers can work together to improve liver health and prevent complications.

Conference Name: 16th World Digestive and Liver Diseases Conference  Short Name: 16DLDUCG2025  Dates: December 17-19, 2025  Venue: Dubai, UAE Email: drfaridaisraeli@gmail.com  Visit: https://digestive-liverdiseases.utilitarianconferences.com/  Visit CME/CPD:  https://digestive-liverdiseases.utilitarianconferences.com/accreditation-registration  Call for Papers: https://digestive-liverdiseases.utilitarianconferences.com/exhibitor-registration  Register here: https://digestive-liverdiseases.utilitarianconferences.com/registration  Exhibitor: https://digestive-liverdiseases.utilitarianconferences.com/exhibitor-registration Sponsor: https://digestive-liverdiseases.utilitarianconferences.com/sponsor-registration  WhatsApp Us: +447723493307 

[drsachinarora]

The Gallbladder and Biliary Tree: Functions, Disorders, and Treatments

The gallbladder and biliary tree play a crucial role in the digestive system, particularly in the digestion and absorption of fats. This blog provides an in-depth look at their anatomy, functions, common disorders, diagnostic methods, and treatments.

Anatomy of the Gallbladder and Biliary Tree

Gallbladder The gallbladder is a small, pear-shaped organ located beneath the liver on the right side of the abdomen. It serves as a storage reservoir for bile, a digestive fluid produced by the liver. The gallbladder measures approximately 7–10 cm in length and can hold about 30–50 ml of bile.

Biliary Tree The biliary tree is a network of ducts that transport bile from the liver to the small intestine. It includes:

Intrahepatic bile ducts – Small ducts within the liver that collect bile from liver cells.

Hepatic ducts – Right and left hepatic ducts merge to form the common hepatic duct.

Cystic duct – Connects the gallbladder to the common hepatic duct, allowing bile storage and release.

Common bile duct (CBD) – Formed by the union of the hepatic duct and cystic duct; it carries bile to the duodenum.

Pancreatic duct – Merges with the CBD at the ampulla of Vater before entering the duodenum.

Functions of the Gallbladder and Biliary Tree

Bile Storage and Concentration – The gallbladder stores and concentrates bile, releasing it when needed for digestion.

Fat Digestion – Bile emulsifies fats, making them easier for pancreatic enzymes to break down.

Excretion of Waste – Bile helps remove bilirubin (a byproduct of red blood cell breakdown) and cholesterol from the body.

Common Disorders of the Gallbladder and Biliary Tree

Gallstones (Cholelithiasis) Gallstones are solid deposits of cholesterol or bilirubin that form in the gallbladder. They may cause symptoms such as abdominal pain, nausea, and vomiting.

Cholecystitis This is inflammation of the gallbladder, often due to gallstones blocking bile flow. Symptoms include severe pain, fever, and jaundice.

Choledocholithiasis This condition occurs when gallstones pass into the common bile duct, leading to bile flow obstruction and possible infection.

Biliary Atresia A congenital disorder where bile ducts are absent or malformed, leading to bile buildup in the liver.

Primary Sclerosing Cholangitis (PSC) A chronic condition causing inflammation and scarring of bile ducts, which can lead to liver failure.

Diagnosis of Gallbladder and Biliary Disorders

Ultrasound – First-line imaging for detecting gallstones and inflammation.

MRCP (Magnetic Resonance Cholangiopancreatography) – Provides detailed images of the biliary tree.

ERCP (Endoscopic Retrograde Cholangiopancreatography) – Used for both diagnosis and treatment of bile duct obstructions.

HIDA Scan – Evaluates gallbladder function and bile flow.

Blood Tests – Check liver function and inflammation markers.

Treatment Options

Medications

Bile acid medications (e.g., ursodeoxycholic acid) may dissolve cholesterol-based gallstones.

Antibiotics for infections like cholecystitis.

Surgical Treatments

Cholecystectomy – Surgical removal of the gallbladder, often performed laparoscopically.

Biliary Drainage – Used to relieve bile duct obstructions.

Non-Surgical Procedures

ERCP – Can remove stones and place stents to clear obstructions.

Lithotripsy – Uses shock waves to break up gallstones.

CONTACT INFORMATION:- Name:- Dr.Sachin Arora (MBBS, M.Ch Surgical Gastroenterologist) Specialist in Laparoscopic GI, HPB, and Gastrointestinal Cancer Surgery 🌐 Website: www.drsachinarora.in 📞 Contact Now: +91-7505209117 📍 Location : Sanjay Medicos, Sector 2, Maharani Bagh Ln, Ballupur Chowk, Ashirwad Enclave, Mohit Nagar, Dehradun, Uttarakhand 248001

Conclusion

The gallbladder and biliary tree are essential for digestion, but they are also susceptible to various disorders. Prompt diagnosis and appropriate treatment are crucial for managing conditions affecting these structures. If you experience persistent digestive symptoms, consult a healthcare provider for proper evaluation and treatment.

[gastroenterologyucgconferences]

The Hidden Dangers of Bile Duct Diseases and Cirrhosis: Protecting Your Liver Health

Our liver, a resilient and vital organ, often works tirelessly in the background, performing numerous essential functions. However, certain conditions can severely impact its health and functionality. Among these are bile duct diseases and cirrhosis, both of which can lead to significant complications if not properly managed. This blog aims to shed light on these conditions, their symptoms, and their treatments.

What Are Bile Duct Diseases?

The bile ducts are a network of tubes that carry bile from the liver to the gallbladder and the small intestine. Bile is crucial for the digestion of fats. When these ducts are compromised, it can lead to serious health issues. Here are some common bile duct diseases:

Primary Biliary Cholangitis (PBC):

What It Is: PBC is an autoimmune condition where the body's immune system attacks the bile ducts within the liver.

Symptoms: Patients often experience fatigue, itching, and jaundice (yellowing of the skin and eyes).

Diagnosis and Treatment: Diagnosed through blood tests for specific antibodies, liver function tests, and imaging studies. Treatment includes medications like ursodeoxycholic acid (UDCA) and obeticholic acid. In severe cases, a liver transplant may be necessary.

Primary Sclerosing Cholangitis (PSC):

What It Is: PSC involves chronic inflammation and scarring of the bile ducts, causing them to narrow.

Symptoms: This condition leads to fatigue, itching, jaundice, and abdominal pain.

Diagnosis and Treatment: Diagnosed through MRCP (magnetic resonance cholangiopancreatography) and ERCP (endoscopic retrograde cholangiopancreatography). Treatment focuses on symptom management, endoscopic procedures to open blocked ducts, and potentially liver transplant.

Biliary Atresia:

What It Is: A congenital condition where the bile ducts are absent or blocked.

Symptoms: Jaundice in newborns, dark urine, pale stools, and poor growth are common signs.

Diagnosis and Treatment: Blood tests, liver biopsy, and imaging studies are used for diagnosis. Surgery (Kasai procedure) is the primary treatment, with liver transplant being necessary in some cases.

Cholangitis:

What It Is: Infection of the bile ducts, often due to gallstone obstruction.

Symptoms: This includes fever, jaundice, and abdominal pain, known collectively as Charcot’s triad.

Diagnosis and Treatment: Diagnosed through blood tests, imaging, and ERCP. Treatment involves antibiotics and procedures to relieve the obstruction.

What is Cirrhosis?

Cirrhosis is the end result of long-term, continuous damage to the liver, leading to permanent scarring (fibrosis). It can result from various liver diseases, including bile duct diseases.

Causes of Cirrhosis

Chronic Alcohol Abuse: Prolonged alcohol consumption can severely damage liver cells, leading to cirrhosis.

Chronic Viral Hepatitis: Hepatitis B and C infections are major contributors.

Non-Alcoholic Steatohepatitis (NASH): Fat accumulation in the liver that causes inflammation and scarring.

Bile Duct Diseases: Conditions like PBC and PSC, which chronically obstruct bile flow, can also lead to cirrhosis.

Symptoms of Cirrhosis

Fatigue and weakness

Jaundice (yellowing of the skin and eyes)

Easy bruising and bleeding

Ascites (fluid accumulation in the abdomen)

Swelling in the legs

Itching

Hepatic encephalopathy (confusion and cognitive impairment)

Diagnosis of Cirrhosis

Physical Examination: Signs of liver disease include jaundice, spider angiomas, and ascites.

Blood Tests: Liver function tests, complete blood count, and clotting profile.

Imaging Studies: Ultrasound, CT scan, or MRI to assess liver size, structure, and complications.

Liver Biopsy: A definitive method to diagnose cirrhosis and assess its severity.

Treatment of Cirrhosis

Medications: To manage symptoms and complications, such as diuretics for ascites and lactulose for hepatic encephalopathy.

Lifestyle Changes: Avoidance of alcohol, a healthy diet, and regular monitoring.

Management of Complications: Endoscopic procedures for varices, paracentesis for ascites, and antibiotics for infections.

Liver Transplant: Considered in advanced cases where the liver is severely damaged.

The Connection Between Bile Duct Diseases and Cirrhosis

Bile duct diseases like PBC and PSC can lead to cirrhosis by causing chronic inflammation and bile flow obstruction. Over time, this chronic damage results in liver scarring, ultimately leading to cirrhosis. Effective management of bile duct diseases is crucial to prevent or delay the onset of cirrhosis.

Conclusion

Bile duct diseases and cirrhosis are complex conditions that require careful medical management. Early diagnosis and treatment are essential to prevent progression and complications. Regular monitoring and a multidisciplinary approach involving hepatologists, gastroenterologists, and other healthcare professionals are key to optimal patient care.

Understanding these conditions and their implications can empower individuals to seek timely medical attention and make informed decisions about their health. Stay proactive about liver health, and consult healthcare providers if you notice any concerning symptoms.

Important Information:

Conference Name: 14th World Gastroenterology, IBD & Hepatology Conference Short Name: 14GHUCG2024 Dates: December 17-19, 2024 Venue: Dubai, UAE Email:  gastroutilitarianconferences@gmail.com Visit: https://gastroenterology.universeconferences.com/ Call for Papers: https://gastroenterology.universeconferences.com/submit-abstract/ Register here: https://gastroenterology.universeconferences.com/registration/ Exhibitor/Sponsor: https://gastroenterology.universeconferences.com/exhibit-sponsor-opportunities/ Call Us: +12073070027 WhatsApp Us: +442033222718

[delveinsight12]

Primary Sclerosing Cholangitis Market Growth Anticipated: Primary Sclerosing Cholangitis Set for Robust Expansion up to 2032, Major Players Include HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics

In the market landscape of Primary Sclerosing Cholangitis, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled  “Primary Sclerosing Cholangitis Market Insights, Epidemiology and Market Forecast, 2032” from DelveInsight. Noteworthy advancements are projected, fueled not only by existing approved therapies but also by the introduction of emerging treatments slated for launch between 2023 and 2032, incremental increase in incidence is reported to impact the market significantly.

The report sheds light on Primary Sclerosing Cholangitis current treatment practices, upcoming drugs in the Primary Sclerosing Cholangitis pipeline, market shares of individual therapies, and the anticipated trajectory of the Primary Sclerosing Cholangitis market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Driving Forces Behind the Primary Sclerosing Cholangitis Market Growth

The overall market of Primary Sclerosing Cholangitis (PSC) is expected to boost due to the expected launch of emerging therapy in the forecasted period (2023–2032).

Discover the Anticipated Evolution and Growth of the Market @ Primary Sclerosing Cholangitis Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

Primary Sclerosing Cholangitis Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others, are actively engaged in developing novel drugs for potential market entry.

Primary Sclerosing Cholangitis Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Primary Sclerosing Cholangitis. Therapies such as HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and others are driving the Primary Sclerosing Cholangitis market.

Primary Sclerosing Cholangitis Epidemiological Trends and Patient Demographics:

According to DelveInsight analysis, in the US the diagnosed prevalence of Primary Sclerosing Cholangitis is higher in males than females.

According to DelveInsight analysis, in EU4 and the UK, the symptomatic cases of Primary Sclerosing Cholangitis are higher than asymptomatic cases. 

Report Features

Details

Geography Coverage

7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Study Period

2019-2032

Market Size

~USD 113 million in 2022

Key Companies

HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others.

The market size of primary sclerosing cholangitis (PSC) is anticipated to increase during the study period, 2019–2032. The expected launch of therapies will lead to change in market dynamics during the forecast period (2023-2032).

Leading Primary Sclerosing Cholangitis Companies and Emerging Drugs: Pioneering companies such as HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, among others, are actively developing novel drugs for potential entry into the Primary Sclerosing Cholangitis market.

Primary Sclerosing Cholangitis Therapeutic Landscape: Key therapies identified for Primary Sclerosing Cholangitis treatment include HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and more.

Primary Sclerosing Cholangitis Overview:

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation, scarring (fibrosis), and narrowing of the bile ducts inside and outside the liver. Over time, this progressive condition can lead to liver damage, cirrhosis, and complications such as liver failure, bile duct infections (cholangitis), and an increased risk of bile duct and liver cancer (cholangiocarcinoma).

Cause: The exact cause of PSC is not fully understood. It is believed to involve an autoimmune component, where the body's immune system mistakenly attacks the bile ducts, leading to inflammation and scarring. PSC is also associated with other autoimmune conditions such as inflammatory bowel disease (IBD), particularly ulcerative colitis.

Symptoms: Many individuals with PSC initially have no symptoms (asymptomatic), but as the disease progresses, they may experience fatigue, itching (pruritus), jaundice (yellowing of the skin and eyes), abdominal pain, fever, weight loss, and complications related to bile duct obstruction or liver damage.

Diagnosis: Diagnosis of PSC involves a combination of blood tests, imaging studies (such as MRI or ERCP), and sometimes a liver biopsy to assess liver tissue for characteristic changes. Additionally, colonoscopy or other tests may be performed to evaluate for associated inflammatory bowel disease.

Treatment: There is no cure for PSC, and treatment primarily focuses on managing symptoms, slowing disease progression, and preventing complications. Medications may be prescribed to relieve itching, manage inflammation, and address complications. In some cases, endoscopic or surgical procedures may be necessary to relieve bile duct blockages.

Monitoring and Complications: Regular monitoring is crucial for individuals with PSC to assess disease progression, manage symptoms, and screen for complications such as liver cirrhosis, bile duct cancer, and other liver-related problems. Liver transplant may be considered for individuals with advanced PSC and severe liver damage or complications.

PSC is a chronic condition that requires ongoing care and monitoring by healthcare providers specializing in gastroenterology or hepatology. Management often involves a multidisciplinary approach, including gastroenterologists, hepatologists, surgeons, and other healthcare professionals, to address various aspects of the disease and optimize treatment strategies.

While treatment can help manage symptoms and slow disease progression, PSC is associated with a risk of complications and may require vigilant long-term management to improve quality of life and reduce the risk of serious liver-related issues.

Key Facts Primary Sclerosing Cholangitis Market Report:

The Primary Sclerosing Cholangitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

According to DelveInsight analysis, the United States accounted for the highest market size of $78 million, with significant market share of PSC in 2022 in the 7MM. The market size of the 7MM is anticipated to increase in the forecast period due to the expected launch of emerging therapy.

Among EU4 and the UK, Germany, Italy, and the UK accounted for the highest market size with approximately 25% each of the total market size in the EU4 and the UK in the year 2022, whileSpainaccounted for the lowest market in the year 2022.

As per DelveInsight estimates, the market size in Japan was approximately USD 4 million in 2022. These numbers are expected to increase during the forecasted period.

Primary Sclerosing Cholangitis Epidemiology Insights:

In 2022, there were about 9,171 diagnosed asymptomatic cases of PSC and 11,038 diagnosed symptomatic cases PSC, in the EU4 and the UK.

As per DelveInsight’s analysts, in Japan, there were approximately 2,443 diagnosed prevalent cases of PSC in the year 2022 accounting for nearly 5% of the total diagnosed prevalent cases of PSC in the 7MM.

Primary Sclerosing Cholangitis Epidemiology Segmentation:

The Primary Sclerosing Cholangitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Primary Sclerosing Cholangitis

• Prevalent Cases of Primary Sclerosing Cholangitis by severity

• Gender-specific Prevalence of Primary Sclerosing Cholangitis

• Diagnosed Cases oF Primary Sclerosing Cholangitis

For in-depth insights, access the full report @ Primary Sclerosing Cholangitis Market Outlook 2032

Related Reports:

Primary Sclerosing Cholangitis Epidemiology Forecast

Primary Sclerosing Cholangitis Epidemiology Forecast report delivers an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Primary Sclerosing Cholangitis Pipeline Insight

Primary Sclerosing Cholangitis Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. 

Healthcare Consulting and Market Research Services by DelveInsight

Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @  Healthcare Market Research Services

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

Connect with DelveInsight:

LinkedIn | Facebook | Twitter

Contact Us:

Kritika Rehani

krehani@delveinsight.com

+91-9650213330

www.delveinsight.com

[miraridoctor]

Itching, medically termed pruritus, is a common distressing symptom in many chronic liver conditions that significantly impairs patient wellbeing. Up to 70% of those with disorders causing cholestasis like primary biliary cholangitis (PBC) and primar... #Mirari #MirariDoctor #MirariColdPlasma #ColdPlasma

[gastrodrkuldeep]

Liver

The treatment for liver-related conditions varies depending on the specific issue you're addressing. I'll provide a general overview of some common liver conditions and their treatments:

Liver Inflammation (Hepatitis): Hepatitis can be caused by viruses (hepatitis A, B, C, etc.) or other factors. Treatment may involve antiviral medications for viral hepatitis, rest, hydration, and managing symptoms. Hepatitis B and C infections, in particular, can sometimes lead to chronic liver disease and may require longer-term management.

Fatty Liver Disease: This condition can result from lifestyle factors such as obesity, excessive alcohol consumption, or certain medications. Treatment involves addressing the underlying causes, such as weight loss, adopting a healthier diet, reducing alcohol intake, and managing any related medical conditions.

Cirrhosis: Cirrhosis is advanced scarring of the liver tissue. It can result from chronic liver disease caused by various factors, including alcohol abuse, hepatitis, or fatty liver disease. Treatment aims to prevent further damage and manage complications. Lifestyle changes, medications, and sometimes even liver transplantation may be considered depending on the severity.

Liver Cancer: Liver cancer can be primary (originating in the liver) or secondary (metastasized from another site). Treatment options include surgery, chemotherapy, radiation therapy, targeted therapies, immunotherapy, and in some cases, liver transplantation.

Autoimmune Liver Diseases: Conditions like autoimmune hepatitis, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) involve the immune system attacking the liver. Treatment may involve immunosuppressive medications to control the immune response and manage inflammation.

Liver Transplantation: For advanced liver diseases that have not responded well to other treatments, liver transplantation may be considered. This involves replacing the diseased liver with a healthy donor liver.

Alcoholic Liver Disease: If alcohol consumption is the cause of liver damage, the primary treatment involves stopping alcohol intake. Other supportive treatments may also be recommended to manage complications.

It's important to note that liver-related treatments should be tailored to the individual's specific condition and medical history. If you or someone you know is dealing with a liver-related issue, it's crucial to consult a qualified healthcare professional for proper diagnosis and treatment recommendations.

[techninja]

Bile Duct Cancer: Understanding the Silent Threat

Introduction:Bile duct cancer, also known as cholangiocarcinoma, is a rare but serious form of cancer that affects the bile ducts. These ducts are responsible for carrying bile, a fluid produced by the liver, to the small intestine. Bile duct cancer is a challenging disease due to its elusive nature and late-stage detection. This article aims to shed light on this silent threat, discussing its causes, symptoms, diagnosis, treatment options, and preventive measures.Causes:The exact cause of bile duct cancer remains unknown. However, certain risk factors have been identified, including chronic inflammation of the bile ducts, such as in cases of primary sclerosing cholangitis (PSC). Other factors that may increase the risk include liver fluke infections, exposure to certain chemicals, smoking, and obesity. Additionally, genetic factors and inherited conditions like Lynch syndrome and Caroli disease can predispose individuals to bile duct cancer.Symptoms:Bile duct cancer often develops without causing noticeable symptoms in its early stages. As the disease progresses, the following symptoms may manifest:1. Jaundice: Yellowing of the skin and eyes due to the accumulation of bilirubin.2. Abdominal pain: Dull or severe pain in the upper abdomen or right side.3. Unexplained weight loss: Sudden and unintentional weight loss without a known cause.4. Itchy skin: Pruritus (itching) resulting from the buildup of bile salts in the skin.5. Pale stools and dark urine: Discoloration of stools (clay-colored) and urine (dark amber) due to inadequate bile flow.Diagnosis:Diagnosing bile duct cancer can be challenging as its symptoms are often nonspecific and resemble those of other liver and gallbladder conditions. Diagnostic procedures may include:1. Imaging tests: Ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic retrograde cholangiopancreatography (ERCP) help visualize the bile ducts and detect abnormalities.2. Tissue biopsy: Removal and examination of a tissue sample to confirm cancerous cells.3. Blood tests: These may include liver function tests, tumor markers, and genetic testing.Treatment:The treatment of bile duct cancer depends on various factors, including the cancer stage, location, and overall health of the patient. Treatment options may include:1. Surgery: Surgical intervention aims to remove the cancerous tissue. This may involve a liver resection, bile duct resection, or liver transplantation.2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.3. Chemotherapy: Anti-cancer drugs are administered orally or intravenously to destroy cancer cells.4. Targeted therapy: Medications specifically designed to target and inhibit cancer cells with certain genetic mutations.5. Palliative care: Focuses on symptom management and improving the quality of life for patients with advanced-stage cancer.Prevention:While bile duct cancer is difficult to prevent, adopting a healthy lifestyle may help reduce the risk. Measures include:1. Avoiding exposure to known carcinogens and chemicals.2. Maintaining a healthy weight through regular exercise and a balanced diet.3. Seeking treatment for underlying liver conditions, such as chronic hepatitis and PSC.4. Limiting alcohol consumption and avoiding smoking.5. Regular check-ups and screenings for individuals at high risk or with a family history of bile duct cancer.Conclusion:Bile duct cancer poses a significant challenge due to its elusive symptoms and late-stage detection. Raising awareness about the disease and its risk factors is crucial for early diagnosis and improved treatment outcomes. Understanding the causes, recognizing the symptoms, and seeking prompt medical attention are essential steps in combating bile duct cancer. By promoting a healthy lifestyle, advocating for regular screenings, and advancing medical research, we can strive to reduce the burden of this silent threat and improve the prognosis for those affected by bile duct cancer.

[businessindustry]

Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033

The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Primary Sclerosing Cholangitis Market?

The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.

What are Primary Sclerosing Cholangitis?                                                                                                                                             

Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389

What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?

The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Type

Classic PSC

Variant PSC

PSC Associated with Autoimmune Hepatitis

PSC with Cholangiocarcinoma

By Treatment Type

Ursodeoxycholic Acid

Obeticholic Acid

Methotrexate

Corticosteroids

Others

By Route of Administration

Oral

Parental

Others

By End-User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Acorda Therapeutics, Inc.

Gilead Sciences, Inc.

NGM Biopharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Falk Pharma GmbH

Allergan Plc.

Shire Plc.

Durect Corporation

Conatus Pharmaceuticals, Inc.

Sirnaomics, Inc.

Shenzhen HighTide Biopharmaceutical Ltd.

Cymabay Therapeutics

Pliant Therapeutics

Immunic AG

View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[kritikarehani]

Primary Sclerosing Cholangitis (PSC) Market Trends 2030

Primary Sclerosing Cholangitis (PSC) is a condition that affects the bile ducts. It occurs because of inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis) and narrowing of the ducts. As a result, bile cannot be released to the gallbladder and small intestine, and it builds up in the liver.

DelveInsight's "Primary Sclerosing Cholangitis (PSC) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Primary Sclerosing Cholangitis (PSC) market report provides current treatment practices, emerging drugs, Primary Sclerosing Cholangitis (PSC) market share of the individual therapies, current and forecasted Primary Sclerosing Cholangitis (PSC) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Primary Sclerosing Cholangitis (PSC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

· The United States

· EU5 (Germany, France, Italy, Spain, and the United Kingdom)

· Japan

Study Period: 2017-2030

Download sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market

Primary Sclerosing Cholangitis (PSC) Disease Understanding and Treatment Algorithm

Primary Sclerosing Cholangitis is thought to arise from a combination of genetic and environmental factors. Researchers believe that genetic changes play a role in this condition because it often occurs in several members of a family and because immediate family members of someone with primary sclerosing cholangitis have an increased risk of developing the condition.  

The symptoms associated with PSC include fatigue and itching (pruritus), followed by yellowing of the skin, mucous membranes, and whites of the eyes (jaundice). Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen.

The DelveInsight Primary Sclerosing Cholangitis (PSC) market report gives a thorough understanding of the Primary Sclerosing Cholangitis (PSC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Primary Sclerosing Cholangitis (PSC). 

Treatment 

It covers the details of conventional and current medical therapies available in the Primary Sclerosing Cholangitis (PSC) market for the treatment of the condition. It also provides Primary Sclerosing Cholangitis (PSC) treatment algorithms and guidelines in the United States, Europe, and Japan. 

Request for sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market

Primary Sclerosing Cholangitis (PSC) Epidemiology  

The Primary Sclerosing Cholangitis (PSC) epidemiology division provide insights about historical and current Primary Sclerosing Cholangitis (PSC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Key facts:

• Primary sclerosing cholangitis is a rare disorder that affects males twice as often as females. Although it may affect individuals of any age, the disorder most often occurs in middle-aged adults.

• The exact incidence and prevalence of the disorder is unknown. One estimate places the incidence at approximately 1 person per each 100,000 in the general population in the United States or Europe.

Primary Sclerosing Cholangitis (PSC) Drug Chapters

In the coming years, the competitive landscape for the Primary Sclerosing Cholangitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  

Major players, such as Gilead Sciences, HighTide Therapeutics, Tobira Therapeutics and NGM Biopharmaceuticals are involved in developing therapies for Primary Sclerosing Cholangitis. Launch of emerging therapies, such as GS-9674 (Gilead Sciences), HTD1801 (HighTide Therapeutics), Cenicriviroc (Tobira Therapeutics) and NGM282 (NGM Biopharmaceuticals) will significantly impact the Primary Sclerosing Cholangitis market during the study period (2017–2030).  

Drug chapter segment of the Primary Sclerosing Cholangitis (PSC) report encloses the detailed analysis of Primary Sclerosing Cholangitis (PSC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Primary Sclerosing Cholangitis (PSC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs 

The report provides the details of the marketed product available for Primary Sclerosing Cholangitis (PSC) treatment. 

Primary Sclerosing Cholangitis (PSC) Emerging Drugs 

The report provides the details of the emerging therapies under the late and mid-stage of development for Primary Sclerosing Cholangitis (PSC) treatment. 

Primary Sclerosing Cholangitis (PSC) Market Outlook

The treatment of PSC focuses on managing the complications and monitoring the liver damage. There have been several medications which are studied in people with Primary Sclerosing Cholangitis, but so far none have been found to slow or reverse the liver damage associated with this disease.

The pharmacotherapy is aimed at treating symptoms and managing complications. Immuno-suppressants, bile salts, chelators (eg, cholestyramine for pruritus), and steroids are used in an attempt to control the disease process but have not shown significant benefit. The further treatment depends on the stage and degree of progression of the disease. There are two major treatment goals in PSC: slow or reverse disease progression and management of symptoms of disease progression.

The Primary Sclerosing Cholangitis (PSC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Primary Sclerosing Cholangitis (PSC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Primary Sclerosing Cholangitis (PSC) market in 7MM is expected to change in the study period 2017-2030.

Click here and get access to our full report.

Click here and request to download our sample pages.

[drpanchallab]

What is primary sclerosing cholangitis?

PSC, or primary sclerosing cholangitis, is a chronic condition in which the bile ducts within and outside the liver become inflamed and scarred, eventually narrowing or blocking them. When this occurs, bile accumulates in the liver, causing liver damage.

**Causes and Symptoms-**The most common symptoms of primary sclerosing cholangitis (PSC) are fatigue and itchy skin. Other symptoms may include weight loss without effort, a loss of appetite, a fever, and abdominal discomfort. The exact etiology of PSC is unknown.

Diagnosis- Primary sclerosing cholangitis is diagnosed based on your medical and family history, a physical exam, and the findings of medical testing such as blood tests and imaging studies. To confirm the diagnosis, your doctor may conduct a liver biopsy.

If you are looking for a diagnostic center, Visit Dr. Panchal Lab and Diagnostics Centre one of the best Diagnostic Centre in Borivali.

[severinetherat]

D is for Diagnosis

Hello, I hope you are all well. Thank you for sticking with me despite my lack of consistent posts. I’m trying to keep with the alphabet theme because it’s more interesting, I think. It also gives my posts a bit more structure, rather than me just rambling.

Anyway, today I want to talk about diagnosis. Specifically, a new diagnosis.

As you should know (if you’ve been following me for a while but don’t worry if not), I have Inflammatory Bowel Disease and Primary Sclerosing Cholangitis, as well as a few other less impressive-sounding conditions. The IBD and PSC I mention specifically because there are thought to be links between them, mainly that patients with Ulcerative Colitis (the form of IBD I have) are more likely to develop PSC than those without UC. This is known as an extraintestinal manifestation which means that other conditions may develop because I have IBD.

Other extraintestinal manifestations include condition such as arthritis, skin conditions, inflammation of the eye, anaemia, problems with the kidneys, and osteoporosis. That last one is what I want to focus on today.

Just to clarify, I do not have osteoporosis. I do, however, have thinning in the base of my spine which they found recently in a bone density scan. This, I believe this is called osteopenia, but I’m not 100% sure as my GP didn’t put a name to it. Anyway, the thinning isn’t too serious, by the sounds of things, but they do want to start a form of treatment to stop it from developing into osteoporosis. My GP is consulting my GI as she doesn’t want to start anything that may aggravate my IBD. In the meantime, I am doing daily exercises that are designed for those with sciatica. This may or may not help but seeing as how I do get mild sciatic symptoms from time to time, I don’t think this will do any harm.

Speaking of exercises, I am still doing my knee exercises, as it doesn get stiff if I've not moved around for a while, and I’ve also added abdominal core exercises to my routine to strengthen my core. My goal is to do them all at least once daily so that I am as strong as I can be to return to work in two weeks. I am also trying to stick to a routine of getting up and going to bed at the same time each day (even the weekends) to regulate my sleep and get my fatigue under control.

Thank you for reading and I hope you are keeping safe and well. Until next time!

[gastroenterologyucgconferences]

Gallbladder and Biliary Diseases: Understanding, Diagnosis, and Treatment

Common Gallbladder and Biliary Diseases

Cholelithiasis (Gallstones):

Types: Cholesterol stones (most common), pigment stones (bilirubin).

Symptoms: Often asymptomatic; can cause biliary colic, nausea, vomiting, jaundice, and acute pancreatitis.

Risk Factors: Obesity, female gender, age, rapid weight loss, pregnancy, certain medications, and genetic predisposition.

Cholecystitis:

Acute Cholecystitis: Inflammation of the gallbladder, usually due to gallstones blocking the cystic duct.

Chronic Cholecystitis: Long-standing inflammation, often associated with gallstones.

Symptoms: Severe right upper quadrant abdominal pain, fever, nausea, vomiting, and tenderness over the gallbladder (Murphy's sign).

Choledocholithiasis:

Gallstones in the common bile duct.

Symptoms: Similar to cholelithiasis but can also cause bile duct obstruction, leading to jaundice and biliary colic.

Cholangitis:

Infection of the bile ducts, often due to obstruction by gallstones.

Symptoms: Charcot’s triad (fever, jaundice, right upper quadrant pain), and in severe cases, Reynolds’ pentad (Charcot’s triad plus hypotension and altered mental status).

Primary Sclerosing Cholangitis (PSC):

Chronic disease causing inflammation and scarring of bile ducts.

Symptoms: Fatigue, pruritus (itching), jaundice, and complications like cirrhosis or liver failure.

Associations: Often linked with inflammatory bowel disease (especially ulcerative colitis).

Biliary Atresia:

A congenital condition where bile ducts are abnormally narrow, blocked, or absent.

Symptoms: Jaundice in newborns, dark urine, pale stools, and failure to thrive.

Treatment: Kasai procedure (hepatoportoenterostomy) and potentially liver transplantation.

Gallbladder Cancer:

Rare but often diagnosed at an advanced stage.

Symptoms: Similar to gallbladder disease but can include weight loss, anorexia, and more persistent pain.

Diagnosis

Imaging Studies:

Ultrasound: First-line for detecting gallstones and assessing gallbladder inflammation.

CT Scan and MRI: Used for more detailed imaging, particularly in complicated cases.

HIDA Scan (Cholescintigraphy): Evaluates gallbladder function and bile flow.

ERCP (Endoscopic Retrograde Cholangiopancreatography): Combines endoscopy and fluoroscopy to diagnose and treat bile duct disorders.

MRCP (Magnetic Resonance Cholangiopancreatography): Non-invasive imaging of the biliary and pancreatic ducts.

Laboratory Tests:

Liver Function Tests: Elevated bilirubin, ALP, GGT, AST, and ALT suggest bile duct obstruction or liver involvement.

Complete Blood Count (CBC): Can indicate infection or inflammation.

Blood Cultures: Useful in cases of suspected cholangitis.

Treatment

Medications:

Antibiotics: For bacterial cholangitis or cholecystitis.

Pain Management: NSAIDs or opioids for pain relief.

Ursodeoxycholic Acid: May help dissolve certain types of gallstones.

Surgical and Non-Surgical Procedures:

Cholecystectomy: Surgical removal of the gallbladder, often laparoscopic.

ERCP: Can remove stones from the common bile duct and place stents.

Percutaneous Transhepatic Cholangiography (PTC): Used for drainage or to relieve obstruction.

Biliary Bypass Surgery: For palliative treatment of biliary obstructions, often in cancer.

Lifestyle and Dietary Changes:

Dietary Modifications: Low-fat diet to reduce symptoms.

Weight Management: Gradual weight loss to reduce risk of gallstones.

Conclusion

Gallbladder and biliary diseases can range from benign to serious conditions. Early diagnosis and appropriate treatment are vital to prevent complications and improve patient outcomes. If you experience any symptoms related to gallbladder or biliary issues, consult your healthcare provider promptly. Regular follow-ups and lifestyle adjustments are crucial for managing chronic conditions and maintaining overall digestive health.

Important Information:

Conference Name: 14th World Gastroenterology, IBD & Hepatology Conference Short Name: 14GHUCG2024 Dates: December 17-19, 2024 Venue: Dubai, UAE Email:  gastroutilitarianconferences@gmail.com Visit: https://gastroenterology.universeconferences.com/ Call for Papers: https://gastroenterology.universeconferences.com/submit-abstract/ Register here: https://gastroenterology.universeconferences.com/registration/ Exhibitor/Sponsor: https://gastroenterology.universeconferences.com/exhibit-sponsor-opportunities/ Call Us: +12073070027 WhatsApp Us: +442033222718